After a decade of Lupin recovering in the corporate equivalent of an ICU, DBG (Desh Bandhu Gupta) did not mistake the consolation of having avoided disaster for good fortune. The decade since 1993 had ...

The EU-India trade deal is set to open Europe up to more Indian medicines, deepening reliance on one of its biggest foreign suppliers when the bloc is trying to bolster its own drug production to ...

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "International Directory of Generics Companies" directory has been added to ResearchAndMarkets.com's offering. This powerful directory is your connection ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...

Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...